NCT07459634
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
At risk: Primary completion moved at least 1 year 6 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 31, 2028 to Aug 4, 2029 Show 4 more changesShow less
- Study completion pushed from Apr 30, 2028 to Nov 4, 2029
- Start date changed from estimate of Nov 30, 2026 to Oct 12, 2026
- Study sites: 5 to 6
- Secondary endpoints: 5 to 6
- Notable Eligibility criteria expanded, about 17 words
- Study sites: 4 to 5
- Notable Start date: Aug 30, 2026 to Nov 30, 2026
- Eligibility criteria shortened, about 7 words
- Study description expanded, about 6 words
- Notable Recruitment opened
- Start date: Jun 12, 2026 to Aug 30, 2026
- Trial sites expanded: 1 → 4 locations
- Notable Start date: Apr 25, 2026 to Jun 12, 2026v3
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Investigator assessed PFS rate
Timeframe: 6 months
Secondary (6)
Investigator assessed PFS
Investigator-assessed confirmed ORR
Number of participants requiring dose modification
Number of participants requiring discontinuations of any component of the combination therapy
Plasma Concentrations of lurbinectedin
Show 1 moreShow less
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Arms and interventions
Durvalumab and lurbinectedin treatment armExperimental
Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen.
Drugs: Lurbinectedin, Durvalumab
Sites
6 sites in 1 country